AZTA — Azenta, Inc.

Summary of Azenta, Inc. Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: $149 million, up 1% reported but down 1% organically, impacted by a 2% headwind from foreign exchange.
• Non-GAAP EPS: $0.09 per share.
• Adjusted EBITDA Margin: 8.5%, down approximately 230 basis points year-over-year, primarily due to pressures in gross margin.
• Free Cash Flow: $15 million for the quarter, with cash and equivalents totaling $571 million, an increase of $25 million quarter-over-quarter.
• Gross Margin: 44.1%, down 360 basis points year-over-year, attributed to underutilized lab capacity and quality issues in automated storage projects.

2. Strategic Updates and Business Highlights

• Turnaround Focus: CEO John Marotta emphasized the ongoing turnaround efforts, highlighting operational excellence, growth acceleration, margin expansion, and disciplined capital deployment as key priorities for 2026.
• Segment Performance:
  • Multiomics: Revenue of $67 million, flat organically, with growth in next-generation sequencing and gene synthesis offset by declines in Sanger sequencing.
  • Sample Management Solutions: Revenue of $81 million, flat reported and down 2% organically, with strong growth in biorepositories but softness in automated stores due to budget constraints.
• Operational Improvements: The Azenta Business System (ABS) is being deployed to enhance efficiency and productivity across operations.
• B Medical Systems Sale: A definitive agreement for the sale is expected to close by March 31, 2026, which will enhance financial flexibility and focus on core operations.

3. Forward Guidance and Outlook

• Full-Year 2026 Guidance: Reaffirmed organic revenue growth of 3% to 5% and adjusted EBITDA margin expansion of approximately 300 basis points.
• Second Half Expectations: Anticipated acceleration in growth driven by improved capital spending, delayed approvals, and the impact of growth investments.

4. Challenges and Points of Concern

• Organic Revenue Decline: A 1% decline in organic revenue was in line with expectations, reflecting ongoing macroeconomic uncertainty and cautious capital spending in the life sciences sector.
• Quality Issues: Ongoing challenges with automated storage projects have led to increased costs and impacted margins, with remediation efforts expected to conclude by the end of Q2.
• Market Conditions: Mixed macro conditions, particularly in North America, are causing delays in capital spending and affecting bookings.
• Sanger Sequencing Decline: Continued weakness in Sanger sequencing raises concerns about future performance in that segment.

5. Notable Q&A Insights

• Gross Margin Confidence: Management expressed confidence in achieving the targeted margin expansion despite challenges, citing operational improvements and cost management efforts.
• Academic and Government Funding: Conversations with customers in the academic sector indicate potential recovery, with expectations for increased funding and spending in the latter half of the year.
• Capital Deployment Strategy: Post-sale of B Medical, Azenta is actively exploring M&A opportunities while maintaining a balanced approach to capital allocation, including share repurchases.
• Regional Performance: Strong growth in China (26% organic growth in NGS) contrasts with softness in North America, highlighting regional disparities in market performance.

Overall, Azenta is navigating a complex environment while focusing on operational improvements and strategic growth initiatives, with cautious optimism for the second half of 2026.